Concert Pharmaceuticals Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Fiserv president resigns, interim leaders named for financial unit
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Roth Boosts PT on Concert Pharma (CNCE) to $22 Following; Deuterium Platform, Partnerships Will Bolster Gains
May 8, 2015 3:08 PM EDTRoth Capital affirms Concert Pharmaceuticals, Inc. (CNCE) at Buy and moves its price target from $19 up to $22 following Q1 results and corporate update issued by the company ahead of the opening bell Friday.
Analyst Joseph Pantginis noted that CNCE reported Q1 loss of $0.48 per share, versus the firm's loss estimate of $0.28 per share.
Pantginis commented, While the stock... More
Concert Pharma (CNCE) Misses Q1 EPS by 4c
May 8, 2015 8:56 AM EDTConcert Pharma (NASDAQ: CNCE) reported Q1 EPS of ($0.48), $0.04 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $2.7 million.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
... More